In präklinischen Wundheilungsmodellen verzögerte die Gabe von EGFR-selektiven Tyrosinkinaseinhibitoren jedoch die Wundheilung.
However, in preclinical wound healing models EGFR selective tyrosine kinase inhibitors were shown to retard wound healing.